|
| Pairing with Medical Service Providers: Getting on the Same Page, Speaking the Same ABC’s |
| Sunday, May 28, 2023 |
| 9:00 AM–9:50 AM |
| Hyatt Regency, Capitol Ballroom 1-3 |
| Area: CBM; Domain: Service Delivery |
| Chair: Michele R. Traub (St. Cloud State University) |
| CE Instructor: Takahiro Soda, M.D. |
| Presenting Author: TAKAHIRO SODA (University of Florida) |
| Abstract: Psychopharmacological agents are prescribed in a high proportion of individuals with ASD/IDD, with several agents with formal FDA-approved indications; many are used off-label. The data-based approach that ABA providers/ RBTs who are supervised by BCBA’s is ideal for contextualizing and measuring the behaviors (e.g., self-injury) for which medications are often considered. As a result, their involvement can tremendously aid in the decision-making process about initiating, adjusting, and discontinuing medications. On the other hand, medical providers (e.g., psychiatrist) can guide the recognition of potential conditions, psychiatric and otherwise that may be leading to sudden changes in target behaviors that have been identified for behavioral intervention. Given these goals and contributions, coordinating care is beneficial and critical. Several examples of achieving such coordination of care will be presented at multiple levels of care with thoughts on how such coordination can be achieved where no ongoing relationships currently exist. |
| Instruction Level: Intermediate |
| Target Audience: Anyone who will have patients/ clients comanaged with psychopharmacology providers, anyone that has had medical concerns for their clients |
| Learning Objectives: At the conclusion of this presentation, participants will be able to: (1) Identify commonly prescribed medication classes and the onset of effects as well as side effects; (2) Understand common context and information typically provided to medical providers when being asked to prescribe various interventions to address behaviors; (3) Identify suggested strategies to interface with medication prescribers to achieve a mutually beneficial relationship |
| |
| TAKAHIRO SODA (University of Florida) |
 Takahiro Soda, MD, PhD is the Medical Director for the UF Health Center for Autism and Neurodevelopment and Assistant Professor of Psychiatry at the University of Florida College of Medicine. His research focuses on bridging the quality gap between the standard of care in the treatment of patients with neuropsychiatric developmental disorders and the quality of care provided in the real world and nudging clinical practice towards the use of patient-specific factors (genetics, environmental/ socioeconomic) to aid in the provision of optimal care of patients and to do so in an equitable and ethical manner. His work has been funded by the NIH, Foundation of Hope for Treatment of Mental Illness, and the UNC Quality Improvement Fellowship. He serves on the ethics as well as the autism/ intellectual developmental disorder committee of the American Academy of Child and Adolescent Psychiatry, and on the Ethics/ Policy Committee of the International Society of Psychiatric Genetics. He is a fellow of the American Psychiatric Association |
|
| |